FERMENTALG (ALGAE.PA)

FR0011271600 - Common Stock

0.405  0 (-0.98%)

Fundamental Rating

3

ALGAE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 62 industry peers in the Chemicals industry. While ALGAE seems to be doing ok healthwise, there are quite some concerns on its profitability. ALGAE is quite expensive at the moment. It does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALGAE had negative earnings in the past year.
ALGAE had a negative operating cash flow in the past year.
ALGAE had negative earnings in each of the past 5 years.
ALGAE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -25.05%, ALGAE is not doing good in the industry: 89.83% of the companies in the same industry are doing better.
With a Return On Equity value of -36.20%, ALGAE is not doing good in the industry: 83.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -25.05%
ROE -36.2%
ROIC N/A
ROA(3y)-18.86%
ROA(5y)-24.61%
ROE(3y)-27.99%
ROE(5y)-42.19%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ALGAE's Gross Margin of 14.04% is on the low side compared to the rest of the industry. ALGAE is outperformed by 76.27% of its industry peers.
In the last couple of years the Gross Margin of ALGAE has declined.
ALGAE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-35.61%
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

ALGAE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALGAE has more shares outstanding
The number of shares outstanding for ALGAE has been increased compared to 5 years ago.
The debt/assets ratio for ALGAE is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.07, we must say that ALGAE is in the distress zone and has some risk of bankruptcy.
ALGAE has a worse Altman-Z score (1.07) than 72.88% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that ALGAE is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.22, ALGAE is doing good in the industry, outperforming 72.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 1.07
ROIC/WACCN/A
WACC5.65%

2.3 Liquidity

ALGAE has a Current Ratio of 3.67. This indicates that ALGAE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.67, ALGAE belongs to the top of the industry, outperforming 86.44% of the companies in the same industry.
A Quick Ratio of 3.42 indicates that ALGAE has no problem at all paying its short term obligations.
ALGAE's Quick ratio of 3.42 is amongst the best of the industry. ALGAE outperforms 93.22% of its industry peers.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.42

More info and screens

6

3. Growth

3.1 Past

ALGAE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.15%.
Looking at the last year, ALGAE shows a very strong growth in Revenue. The Revenue has grown by 69.31%.
Measured over the past years, ALGAE shows a very strong growth in Revenue. The Revenue has been growing by 75.18% on average per year.
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.05%
Revenue 1Y (TTM)69.31%
Revenue growth 3Y22.55%
Revenue growth 5Y75.18%
Sales Q2Q%170.04%

3.2 Future

Based on estimates for the next years, ALGAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.35% on average per year.
Based on estimates for the next years, ALGAE will show a very strong growth in Revenue. The Revenue will grow by 68.64% on average per year.
EPS Next Y45.83%
EPS Next 2Y33.85%
EPS Next 3Y25.11%
EPS Next 5Y15.35%
Revenue Next Year200%
Revenue Next 2Y113.02%
Revenue Next 3Y91.29%
Revenue Next 5Y68.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALGAE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALGAE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ALGAE's earnings are expected to grow with 25.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.85%
EPS Next 3Y25.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGAE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FERMENTALG

EPA:ALGAE (1/14/2025, 7:00:00 PM)

0.405

0 (-0.98%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-03 2024-10-03
Earnings (Next)01-23 2025-01-23/amc
Inst Owners25.99%
Inst Owner ChangeN/A
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap34.90M
Analysts82
Price Target0.55 (35.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)13.83%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-18.18%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.34
P/FCF N/A
P/OCF N/A
P/B 0.89
P/tB 1.45
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.09
BVpS0.45
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.05%
ROE -36.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.04%
FCFM N/A
ROA(3y)-18.86%
ROA(5y)-24.61%
ROE(3y)-27.99%
ROE(5y)-42.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-35.61%
GM growth 5YN/A
F-Score3
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.41%
Cap/Sales 6.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.42
Altman-Z 1.07
F-Score3
WACC5.65%
ROIC/WACCN/A
Cap/Depr(3y)114.7%
Cap/Depr(5y)105.41%
Cap/Sales(3y)21.78%
Cap/Sales(5y)42.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.05%
EPS Next Y45.83%
EPS Next 2Y33.85%
EPS Next 3Y25.11%
EPS Next 5Y15.35%
Revenue 1Y (TTM)69.31%
Revenue growth 3Y22.55%
Revenue growth 5Y75.18%
Sales Q2Q%170.04%
Revenue Next Year200%
Revenue Next 2Y113.02%
Revenue Next 3Y91.29%
Revenue Next 5Y68.64%
EBIT growth 1Y-24.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30%
EBIT Next 3Y30.06%
EBIT Next 5Y19.28%
FCF growth 1Y59.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.19%
OCF growth 3YN/A
OCF growth 5YN/A